SomnoMed (SOM) Q4 2025 TU earnings summary

Executive summary

• Q4 FY25 revenue reached $30.1m, up 25.1% year-over-year, with strong growth in Europe and North America.

• FY25 full year revenue was $111.5m, exceeding guidance and up 21.6% year-over-year.

• Surpassed 1 million patients treated during FY25 H2, reinforcing global market leadership.

• Facility expansion underway to add at least 25% capacity in FY26.

Financial highlights

• Q4 FY25 revenue: $30.1m (+25.1% vs Q4 FY24); FY25 revenue: $111.5m (+21.6% vs FY24).

• FY25 EBITDA expected at the top end of $7m–$9m guidance range.

• FY25 positive free cash flow of $0.8m; net cash inflow from operations of $4.9m.

• Cash balance at 30 June 2025: $17.3m; net cash balance: $16.5m.

• Capex spend for FY25 totaled $4.1m.

Outlook and guidance

• Facility expansion to deliver at least 25% additional capacity in FY26.

• Second round of cost optimisation underway, with $1.0m in one-off restructuring costs expected.

• Ongoing savings from restructuring to be redeployed across the business.